KCM
CPRX icon

Kingdon Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Kingdon Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-756,311
Closed -$794K – 112
2016
Q4 		$794K Buy
+756,311
New +$864K 0.04% 118

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return

Kingdon Capital Management's CPRX Position: Q1 2017 in Review

Kingdon Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2017, closing a stake of 756,311 shares — an estimated $794K sold.

Kingdon Capital Management first reported a position in CPRX in Q4 2016 and held it in 1 quarter. The position peaked at $794K in Q4 2016. 50 funds tracked by Wall St. Rank hold CPRX as of Q1 2017.

  • Kingdon Capital Management reported no remaining Catalyst Pharmaceutical position as of Q1 2017 after selling out during the quarter.
  • Kingdon Capital Management sold 756,311 Catalyst Pharmaceutical shares in Q1 2017, an estimated $794K.
  • Kingdon Capital Management first reported a position in Catalyst Pharmaceutical in Q4 2016 and held it in 1 quarter.
  • Kingdon Capital Management's Catalyst Pharmaceutical position peaked at $794K in Q4 2016.
  • 50 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2017.

Based on Kingdon Capital Management's 13F filing for Q1 2017, filed 15 May 2017.